ArticleScientific reports2026
Global profiling of protein lactylation in pancreatic ductal adenocarcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer cells dramatically increase L-lactate production, fueling lysine lactylation (Kla) – a posttranslational modification that rewires protein function and links metabolic flux to gene and pathway regulation. Although emerging studies implicate Kla in diverse diseases, its role in pancreatic ductal adenocarcinoma (PDAC) remains poorly understood. Here, we performed global lactylomic profiling of immunoprecipitated lactylated proteins from PDAC and normal pancreatic cell lines, as well as from patient-derived tumors and adjacent normal tissues. Mass spectrometry revealed distinct Kla signatures that separated PDAC from normal pancreas, with a higher number of Kla sites per protein in tumors. Functional enrichment analysis with the Database for Annotation, Visualization, and Integrated Discovery (DAVID) revealed significant enrichment of lactylated proteins involved in metabolic and signaling pathways, including insulin resistance and choline metabolism, in PDAC. The analysis also shows that PDAC cells and tumors exhibit preferential Kla associated with neurodevelopmental disorders, particularly intellectual disability. These findings suggest that Kla distinguishes PDAC from normal pancreas and may provide molecular insight into the metabolic and neurological comorbidities observed in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.